1. Report Introduction 2. Atopic Dermatitis Market Overview at a Glance 2.1. Market Share Distribution of Atopic Dermatitis in 2017 2.2. Market Share Distribution of Atopic Dermatitis in 2027 3. Disease Background and Overview 3.1. Etiology 3.2. Risk Factors 3.3. Pathophysiology 3.4. Atopic Dermatitis 3.4.1. Pruritus Associated with Atopic Dermatitis 3.4.2. Diagnosis 4. Epidemiology and Patient Population 4.1. Disease Definition 4.2. Population and Forecast Parameters 4.3. Population Methods 4.3.1. Total prevalent cases in US 4.3.2. EU5 4.3.3. Japan 4.4. Prevalent Population of Atopic Dermatitis in 7MM 4.5. Prevalent Population of Atopic Dermatitis in United States 4.6. Prevalent Population of Atopic Dermatitis in Germany 4.7. Prevalent Population of Atopic Dermatitis in France 4.8. Prevalent Population of Atopic Dermatitis in Italy 4.9. Prevalent Population of Atopic Dermatitis in Spain 4.10. Prevalent Population of Atopic Dermatitis in United Kingdom 4.11. Prevalent Population of Atopic Dermatitis in Japan 4.12. Prevalent Population of Atopic Dermatitis by Severity in 7MM 4.13. Prevalent Population of Atopic Dermatitis by Severity in Children in 7MM 4.14. Prevalent Population of Atopic Dermatitis by Severity in Adults in 7MM 4.15. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM 4.16. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases 4.17. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM 4.18. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM 5. Treatment Practices 6. Treatment Algorithm 6.1. Treatment Goals 6.2. Treatment Guidelines by American Academy of Dermatology 6.3. Japanese Guidelines for Atopic Dermatitis 2017 6.4. Guidelines on the Treatment of Atopic Eczema (Atopic Dermatitis): European Dermatology Forum 7. Treatment Failure 7.1. Approved Drugs for Atopic Dermatitis 8. Emerging Therapies 9. Nemolizumab: Galderma Pharma 9.1. Product Description 9.2. Research and Development 9.3. Product Development Activities 10. Tralokinumab: LEO Pharma 10.1. Product Description 10.2. Research and Development 10.3. Product Development Activities 11. Tradipitant: Vanda Pharmaceuticals 11.1. Product Description 11.2. Research and Development 11.3. Product Development Activities 12. ZPL-389: Novartis 12.1. Product Description 12.2. Research and Development 12.3. Product Development Activities 13. NST-141: Nippon Shinyaku 13.1. Product Description 13.2. Research and Development 13.3. Product Development Activities 14. Serlopitant: Menlo Therapeutics 14.1. Product Description 14.2. Research and Development 14.3. Product Development Activities 15. DS107: DS Biopharma 15.1. Product Description 15.2. Research and Development 15.3. Product Development Activities 16. Asimadoline: Tioga Pharmaceuticals 16.1. Product Description 16.2. Research and Development 16.3. Product Development Activities 17. GSK2894512: GlaxoSmithKline 17.1. Product Description 17.2. Research Development Activities 17.3. Product Development Activities 18. Lebrikizumab: Roche 18.1. Product Description 18.2. Research and Development 19. DMT210: Dermata Therapeutics 19.1. Product Description 19.2. Research and Development 19.3. Product Development Activities 20. RVT-501: Roivant Sciences 20.1. Product Description 20.2. Research and Development 20.3. Product Development Activities 21. OPA-15406: Otsuka Pharmaceutical 21.1. Product Description 21.2. Research and Development 21.3. Product Development Activities 22. Current Unmet Need 23. Atopic Dermatitis: Market Analysis 23.1. Market Outlook-7MM 23.2. Market size of Atopic Dermatitis in 7MM 24. Atopic Dermatitis: United States Market Outlook 24.1. United States Market size 25. Atopic Dermatitis: EU5 Market Outlook 25.1. Germany Market size 25.2. France Market size 25.3. Italy Market size 25.4. Spain Market size 25.5. United Kingdom Market size 26. Atopic Dermatitis: Japan Market Outlook 26.1. Japan Market size 27. Market Drivers 28. Market Barriers 29. Expert Opinions 30. Views on Current treatment options 31. Views on emerging therapies 32. Appendix 33. Report Methodology 33.1. Source Used 34. DelevInsight Capabilities 35. Disclaimer 36. About DelveInsight

Table 1: Targets focused by companies Table 2: Concept of Atopic Dermatitis by Wise and Sulzberger Table 3: Hanifin and Rajka Diagnostic Criteria Table 4: United Kingdom Working Party diagnostic criteria Table 5: American Academy of Dermatology Diagnostic Criteria Table 6: Japanese Dermatological Association Diagnostic Criteria Table 7: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027) Table 8: Prevalent Population of Atopic Dermatitis in United States (2016-2027) Table 9: Prevalent Population of Atopic Dermatitis in Germany (2016-2027) Table 10: Prevalent Population of Atopic Dermatitis in France (2016-2027) Table 11: Prevalent Population of Atopic Dermatitis in Italy (2016-2027) Table 12: Prevalent Population of Atopic Dermatitis in Spain (2016-2027) Table 13: Prevalent Population of Atopic Dermatitis in United Kingdom (2016-2027) Table 14: Prevalent Population of Atopic Dermatitis in Japan (2016-2027) Table 15: Prevalent Cases of Atopic Dermatitis by Severity in 7MM Table 16: Prevalent Cases of Atopic Dermatitis by Severity in Children in 7MM Table 17: Prevalent Cases of Atopic Dermatitis by Severity in Adult in 7MM Table 18: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027) Table 19: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027) Table 20: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027) Table 21:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027) Table 22: Topical corticosteroids used for the treatment of Atopic Dermatitis Table 23: Topical Calcineurin Inhibitors (TCIs) Table 24: Topical Phosphodiesterase Type-4 (PDE4) inhibitors Table 25: Oral Corticosteroids Table 26: Biologic medications Table 27: Non-approved systemic immunomodulating agents Table 28: Reasons for noncompliance with medication Table 29: Emerging therapies Table 30: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027) Table 31: Market Size of Atopic Dermatitis in United States, USD Millions (2016-2027) Table 32: Market Size of Atopic Dermatitis in Germany , USD Million (2016-2027) Table 33: Market Size of Atopic Dermatitis in France, USD Million (2016-2027) Table 34: Market Size of Atopic Dermatitis in Italy, USD Million (2016-2027) Table 35: Market Size of Atopic Dermatitis in Spain , USD Million (2016-2027) Table 36: Market Size of Atopic Dermatitis in United Kingdom, USD Million (2016-2027) Table 37:Market Size of Atopic Dermatitis in Japan , USD Million (2016-2027) Figure 1: Risk Factors for Atopic Dermatitis Figure 2: Summary of pathogenic mechanisms in acute and chronic atopic dermatitis (AD) Figure 3: Pathophysiology of Pruritus in Atopic Dermatitis Figure 4: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis Figure 5: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027) Figure 6: Total Prevalent Population of Atopic Dermatitis in United States (2016-2027) Figure 7: Total Prevalent Population of Atopic Dermatitis in Germany (2016-2027) Figure 8: Total Prevalent Population of Atopic Dermatitis in France (2016-2027) Figure 9: Total Prevalent Population of Atopic Dermatitis in Italy (2016-2027) Figure 10: Total Prevalent Population of Atopic Dermatitis in Spain (2016-2027) Figure 11: Total Prevalent Population of Atopic Dermatitis in the United Kingdom (2016-2027) Figure 12: Total Prevalent Population of Atopic Dermatitis in Japan (2016-2027) Figure 13: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027) Figure 14: Total Prevalent Population of Atopic Dermatitis by Severity in Children in 7 MM (2016-2027) Figure 15: Total Prevalent Population of Atopic Dermatitis by Severity in Adult in 7 MM (2016-2027) Figure 16: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027) Figure 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027) Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027) Figure 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027) Figure 20: General Treatment for Atopic Dermatitis Figure 21: First Line and second line treatment of Atopic Dermatitis Figure 22: Current stepped treatment options for Atopic dermatitis Figure 23: Current Unmet Need for Atopic Dermatitis Figure 24: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027) Figure 25: Market Size of Atopic Dermatitis in United States, USD Millions (2016-2027) Figure 26: Market Size of Atopic Dermatitis in Germany , USD Million (2016-2027) Figure 27: Market Size of Atopic Dermatitis in France, USD Million (2016-2027) Figure 28: Market Size of Dermatitis in Italy, USD Million (2016-2027) Figure 29: Market Size of Atopic Dermatitis in Spain, USD Million (2016-2027) Figure 30: Market Size of Atopic Dermatitis in United Kingdom , USD Million (2016-2027) Figure 31:Market Size of Atopic Dermatitis in Japan , USD Million (2016-2027)